Compare Stocks: CUPR, NEPH, RMTI, and RVP

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CUPR Cuprina Holdings (Cayman)	$2.07 +4.0%	$2.58	$1.45 ▼ $14.80	$14.51M	-0.1	1.09 million shs	2,985 shs
NEPH Nephros	$3.61 +2.6%	$4.11	$2.66 ▼ $6.42	$38.23M	1.64	32,319 shs	563 shs
RMTI Rockwell Medical	$7.53 -1.7%	$7.96	$4.89 ▼ $12.90	$30.35M	1.63	42,226 shs	9,741 shs
RVP Retractable Technologies	$0.60 -2.5%	$0.70	$0.58 ▼ $1.14	$17.87M	1.2	55,867 shs	1,068 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CUPR Cuprina Holdings (Cayman)	+4.74%	0.00%	-37.52%	-50.37%	+198,999,900.00%
NEPH Nephros	-1.95%	+10.00%	-20.54%	-6.38%	-34.57%
RMTI Rockwell Medical	-2.42%	-6.81%	-1.54%	+33.68%	-36.17%
RVP Retractable Technologies	-2.77%	-14.14%	-13.04%	-14.17%	-35.32%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CUPR Cuprina Holdings (Cayman)	$2.07 +4.0%	$2.58	$1.45 ▼ $14.80	$14.51M	-0.1	1.09 million shs	2,985 shs
NEPH Nephros	$3.61 +2.6%	$4.11	$2.66 ▼ $6.42	$38.23M	1.64	32,319 shs	563 shs
RMTI Rockwell Medical	$7.53 -1.7%	$7.96	$4.89 ▼ $12.90	$30.35M	1.63	42,226 shs	9,741 shs
RVP Retractable Technologies	$0.60 -2.5%	$0.70	$0.58 ▼ $1.14	$17.87M	1.2	55,867 shs	1,068 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CUPR Cuprina Holdings (Cayman)	+4.74%	0.00%	-37.52%	-50.37%	+198,999,900.00%
NEPH Nephros	-1.95%	+10.00%	-20.54%	-6.38%	-34.57%
RMTI Rockwell Medical	-2.42%	-6.81%	-1.54%	+33.68%	-36.17%
RVP Retractable Technologies	-2.77%	-14.14%	-13.04%	-14.17%	-35.32%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CUPR Cuprina Holdings (Cayman)	1.00	Sell	N/A	N/A
NEPH Nephros	2.25	Hold	$4.00	10.80% Upside
RMTI Rockwell Medical	2.00	Hold	$20.00	165.60% Upside
RVP Retractable Technologies	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest RVP, NEPH, RMTI, and CUPR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/13/2026	CUPR Cuprina Holdings (Cayman)	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
10/8/2026	RMTI Rockwell Medical	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
9/21/2026	RMTI Rockwell Medical	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
9/11/2026	RMTI Rockwell Medical	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$20.00
9/3/2026	RMTI Rockwell Medical	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
8/26/2026	CUPR Cuprina Holdings (Cayman)	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
8/20/2026	RMTI Rockwell Medical	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
8/18/2026	NEPH Nephros	Benchmark Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Speculative Buy
8/11/2026	CUPR Cuprina Holdings (Cayman)	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
8/6/2026	RMTI Rockwell Medical	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
8/3/2026	NEPH Nephros	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold (C-) ➝ Hold (C)

(Data available from 10/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CUPR Cuprina Holdings (Cayman)	$49.89K	290.58	N/A	N/A	$1.50 per share	1.38
NEPH Nephros	$20.72M	1.89	$0.13 per share	28.62	$0.96 per share	3.76
RMTI Rockwell Medical	$69.26M	0.44	N/A	N/A	$9.38 per share	0.80
RVP Retractable Technologies	$33.90M	0.53	$0.01 per share	48.25	$3.31 per share	0.18

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CUPR Cuprina Holdings (Cayman)	-$3.63M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NEPH Nephros	$1.19M	$0.16	22.56	11.65	N/A	8.38%	10.60%	8.05%	11/5/2026 (Estimated)
RMTI Rockwell Medical	-$5.31M	-$1.34	N/A	20.92	N/A	-7.33%	-14.03%	-8.90%	11/11/2026 (Estimated)
RVP Retractable Technologies	-$7.01M	-$0.12	N/A	N/A	N/A	-41.11%	-17.15%	-9.33%	N/A

Latest RVP, NEPH, RMTI, and CUPR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/11/2026	Q3 2026	RMTI Rockwell Medical	-$0.13	N/A	N/A	N/A	$18.22 million	N/A
11/5/2026	Q3 2026	NEPH Nephros	$0.02	N/A	N/A	N/A	$5.49 million	N/A
8/13/2026	Q2 2026	RMTI Rockwell Medical	-$0.2350	-$0.34	-$0.1050	-$0.34	$17.82 million	$17.78 million
8/6/2026	Q2 2026	NEPH Nephros	$0.0033	$0.06	+$0.0567	$0.11	$4.99 million	$6.02 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CUPR Cuprina Holdings (Cayman)	N/A	N/A	N/A	N/A	N/A
NEPH Nephros	N/A	N/A	N/A	N/A	N/A
RMTI Rockwell Medical	N/A	N/A	N/A	N/A	N/A
RVP Retractable Technologies	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CUPR Cuprina Holdings (Cayman)	N/A	N/A	N/A
NEPH Nephros	N/A	4.07	2.71
RMTI Rockwell Medical	0.21	3.25	3.00
RVP Retractable Technologies	0.01	8.57	5.92

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CUPR Cuprina Holdings (Cayman)	N/A
NEPH Nephros	41.10%
RMTI Rockwell Medical	23.31%
RVP Retractable Technologies	7.58%

Insider Ownership

Company	Insider Ownership
CUPR Cuprina Holdings (Cayman)	N/A
NEPH Nephros	6.70%
RMTI Rockwell Medical	4.60%
RVP Retractable Technologies	59.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CUPR Cuprina Holdings (Cayman)	10	7.00 million	N/A	N/A
NEPH Nephros	36	10.86 million	10.13 million	Not Optionable
RMTI Rockwell Medical	157	4.03 million	3.85 million	Optionable
RVP Retractable Technologies	201	29.94 million	13.47 million	Optionable

RVP, NEPH, RMTI, and CUPR Headlines

Recent News About These Companies

Retractable Technologies Announces Dividend for Series II and III Preferred Stockholders

October 2, 2026 | kalkinemedia.comK

Retractable Technologies, Inc. Declares Dividends to Series II and III Class B Preferred Stock Shareholders

September 30, 2026 | businesswire.com

Retractable Technologies, Inc. Supports Senator Blackburn’s ONSHORE Manufacturing Act

September 3, 2026 | finance.yahoo.com

Retractable Technologies, Inc. Supports Senator Blackburn's ONSHORE Manufacturing Act

September 3, 2026 | businesswire.com

RVP Stock Gains Post Q2 Earnings Despite Fall in Sales & Unit Volumes

August 20, 2026 | zacks.com

Retractable Technologies, Inc. Results for the Periods Ended June 30, 2026

August 14, 2026 | businesswire.com

Retractable Technologies, Inc. Declares Dividends to Series II and III Class B Preferred Stock Shareholders

June 30, 2026 | businesswire.com

Retractable Stock Slips Post Q1 Earnings, Sales Decline Y/Y

May 21, 2026 | zacks.com

Retractable Technologies, Inc. Results for the Period Ended March 31, 2026

May 15, 2026 | businesswire.com

Retractable Technologies Shareholders Reelect Class 2 Directors

May 13, 2026 | tipranks.com

Retractable Technologies, Inc. Announces Workforce Reduction

April 9, 2026 | businesswire.com

Retractable Technologies Analyst Ratings and Price Targets | AMEX:RVP | Benzinga

April 9, 2026 | benzinga.com

RVP Stock Plunges Post Q4 Earnings Despite Revenue Growth

April 1, 2026 | zacks.com

Retractable Technologies Declares Preferred Dividend Amid Tariff Pressures

March 27, 2026 | tipranks.com

Retractable Technologies: Q4 Earnings Snapshot

March 27, 2026 | houstonchronicle.comH

Retractable Technologies, Inc. Reports Results for 2025

March 27, 2026 | businesswire.com

Retractable Technologies, Inc. Declares Dividends to Series II and III Class B Preferred Stock Shareholders

March 27, 2026 | businesswire.com

RVP Stock Rises Post Q3 Earnings Despite Tariff and Cost Pressures

November 20, 2025 | zacks.com

Retractable Technologies, Inc. Results for the Periods Ended September 30, 2025

November 14, 2025 | businesswire.com

Retractable Technologies, Inc. Receives Innovative Technology Designation from Vizient for EasyPoint Blood Collection Tube Holder with Needle

November 14, 2025 | businesswire.com

Media Sentiment Over Time

CUPR, NEPH, RMTI, and RVP Company Descriptions

Cuprina Holdings (Cayman) NASDAQ:CUPR

$2.07 +0.08 (+4.02%)

As of 10:13 AM Eastern

We are a Singapore-based biomedical and biotechnology company that is dedicated to the development and commercialization of innovative products for the management of chronic wounds, as well as operating in the health and beauty sectors. Our expertise in biomedical research allows us to identify and utilize materials derived from natural sources to develop wound care products in the form of medical devices which meet international standards. We believe we will be able to build upon and leverage such expertise to develop innovative cosmeceutical products in the future. As of June 30, 2024, we manufactured and distributed a line of medical grade sterile blowfly larvae bio-dressing products marketed under the MEDIFLY brand name, or the MEDIFLY products. The MEDIFLY products are used as a biological debridement tool for chronic wounds, in a procedure known as Maggot Debridement Therapy, or MDT, which is an effective alternative to surgical debridement. In addition to our currently commercialized MEDIFLY products, we have two lines of chronic wound care products in our pipeline. Such lines of pipeline chronic wound care products include: . Collagen dressings, including sponges, particles and hydrogels utilizing bullfrog collagen derived from the valorization of abattoir waste streams of American bullfrogs (Lithobates catesbeianus); and . Products utilizing medical leeches for wound treatment. We currently expect development of such products to take place over the course of 2025 and 2026 and to become commercially available subject to regulatory approval. However, we may not be able to successfully develop the aforementioned pipeline products on the timeline currently envisioned, or at all, and even if we do, these products may not receive the necessary regulatory approvals from the authorities in the intended markets where we plan to introduce them. We believe what sets us apart is our focus on developing functionally specific chronic wound care products designed to address the major stages of wound healing process, from chronic to closure. Our chronic wound care products, including both our existing commercialized products and forthcoming products in our pipeline, are poised to benefit from escalating global market demand. This demand is primarily fueled by the demographic shift towards an aging population and the concurrent rise in comorbidities such as diabetes, obesity, cardiovascular ailments, and peripheral vascular diseases. We either self-develop our chronic wound care products or co-develop them through technology licensing agreements or research collaboration with a renowned research university. In June 2022, we were granted an exclusive license from NTUitive Pte. Ltd., a wholly owned subsidiary of Nanyang Technological University, to develop and commercialize a range of chronic wound care products using collagen derived from bullfrog skin. In addition, in August 2022, we entered into an industry research collaboration agreement with Nanyang Technological University, or, together with its subsidiaries, NTU, pursuant to which both parties agreed to jointly undertake a research project regarding the development and validation of bullfrog skin waste to generate collagen-based wound care products. We have been selling our MEDIFLY products primarily in Singapore since February 2020. In March 2023, our MEDIFLY products became commercially available in Hong Kong. Looking ahead, we have strategic plans in place for 2025 and 2026 to expand our sales and establish physical operations in several key regions, including the Middle East (in particular, the member states of the Gulf Cooperation Council, or GCC), and mainland China. These expansion initiatives will further enable us to cater to the growing demand for our products in these promising markets, cementing our position as a trusted player in the field of chronic wound care and treatment. For our cosmeceuticals business, we introduced three products in 2023, including a hydrating balm product, a muscle energy cream and a pain relief muscle patch. For our currently commercialized cosmeceutical products, we have commissioned original equipment manufacturers of skincare products to develop the formulation and manufacture the substantially finished and finished products. In addition, we plan to explore the possibility of developing a range of potential cosmeceutical product candidates incorporating bullfrog collagen with a view to making them commercially available between 2025 and 2028, subject to the progress of the relevant R&D work. We offer our chronic wound care products to both public and private hospitals and clinics, where patients can obtain them through prescription from a physician. Our customers primarily include major public and private hospitals and clinics in Singapore. Our commercialized cosmeceutical products can be purchased directly by individual customers through a variety of channels, including retailers and gyms in Singapore and other countries such as Malaysia and Australia, as well as online shopping platforms such as Shopee. Our commitment to quality is demonstrated by our attainment of ISO 13485:2016 standards for Quality Management Systems and Manufacturing Processes and Controls for our manufacturing facility located in Singapore in 2020. We are working towards obtaining compliance with 21 CFR Part 820, an integral component of the Current Good Manufacturing Practice, or CGMP, regulations, to secure FDA 510(k) clearance for our chronic wound care products, including both our existing commercialized products and forthcoming products in our pipeline. Our principal executive office is in Singapore.

Nephros NASDAQ:NEPH

$3.61 +0.09 (+2.56%)

As of 10:14 AM Eastern

Nephros, Inc., a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company also manufactures and sells water filters that enhance the taste and odor of water, as well as reduce biofilm, cysts, particulates, and scale build-up in downstream equipment. It markets its products to food service, hospitality, convenience store, and health care markets, as well as medical institutions. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey.

Rockwell Medical NASDAQ:RMTI

$7.53 -0.13 (-1.70%)

As of 10:14 AM Eastern

Rockwell Medical, Inc., together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. The company offers Triferic Dialysate and Triferic AVNU which are indicated to maintain hemoglobin in adult undergoing hemodialysis. It also manufactures, sells, delivers, and distributes hemodialysis concentrates, such as CitraPure citric acid concentrate, Dri-Sate dry acid concentrate, RenalPure liquid acid concentrate, dry acid concentrate mixer, and RenalPure and SteriLyte powder bicarbonate concentrate; and ancillary products, including testing supplies, 5% acetic acid cleaning solution, 5% and 2% citric acid descaler, filtration salts, and other items used by hemodialysis providers. The company's hemodialysis concentrate products are used to sustain patient's life by removing toxins and balancing electrolytes in a dialysis patient's bloodstream. The company serves to hemodialysis clinics. Rockwell Medical, Inc. was incorporated in 1996 and is headquartered in Wixom, Michigan.

Retractable Technologies NYSE:RVP

$0.60 -0.02 (-2.46%)

As of 10:15 AM Eastern

Retractable Technologies, Inc. designs, develops, manufactures, and markets safety syringes and other safety medical products for the healthcare profession in the United States, rest of North and South America, and internationally. The company offers VanishPoint insulin syringes; tuberculin, insulin, and allergy antigen syringes; small diameter tube adapters; blood collection tube holders; allergy trays; IV safety catheters; Patient Safe syringes and Luer Caps; VanishPoint blood collection sets; EasyPoint needles; and VanishPoint autodisable syringes. It distributes its products through general line and specialty distributor; international distributors; and a direct marketing network. Retractable Technologies, Inc. was incorporated in 1994 and is headquartered in Little Elm, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RVP, NEPH, RMTI, and CUPR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RVP, NEPH, RMTI, and CUPR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RVP, NEPH, RMTI, and CUPR Headlines

Recent News About These Companies

Media Sentiment Over Time

CUPR, NEPH, RMTI, and RVP Company Descriptions

Cuprina Holdings (Cayman) NASDAQ:CUPR

Nephros NASDAQ:NEPH

Rockwell Medical NASDAQ:RMTI

Retractable Technologies NYSE:RVP

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RVP, NEPH, RMTI, and CUPR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RVP, NEPH, RMTI, and CUPR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RVP, NEPH, RMTI, and CUPR Headlines

Recent News About These Companies

Media Sentiment Over Time

CUPR, NEPH, RMTI, and RVP Company Descriptions

Cuprina Holdings (Cayman) NASDAQ:CUPR

Nephros NASDAQ:NEPH

Rockwell Medical NASDAQ:RMTI

Retractable Technologies NYSE:RVP

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools